Unichem Laboratories Limited announced that it has received ANDA approval for its Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Ranexa®? (ranolazine extended-release tablets) 500 mg and 1,000 mg, of Gilead Sciences Inc. Ranolazine Extended-Release Tablets, 500 mg, and 1,000 mg are indicated for the treatment of chronic angina. The product will be commercialized from Unichem's Goa Plant.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
536.2 INR | -1.58% |
|
+0.94% | +31.76% |
1st Jan change | Capi. | |
---|---|---|
+31.76% | 459M | |
+54.61% | 811B | |
+44.25% | 640B | |
-6.33% | 353B | |
+20.62% | 333B | |
+10.44% | 302B | |
+18.45% | 246B | |
+2.09% | 225B | |
+13.03% | 218B | |
+8.61% | 168B |
- Stock Market
- Equities
- UNICHEMLAB Stock
- News Unichem Laboratories Limited
- Unichem Laboratories Limited Receives ANDA Approval for its Ranolazine Extended-Release Tablets, 500 Mg and 1,000 Mg from the United States Food and Drug Administration